|
1 Indications And Usage Benlysta (Belimumab) Is Indicated For The Treatment Of Patients Aged 5 Years And Older With Active, Autoantibody ‑ Positive, Systemic Lupus Erythematosus (Sle) Who Are Receiving Standard Therapy. Limitations Of Use The Efficacy Of Benlysta Has Not Been Evaluated In Patients With Severe Active Lupus Nephritis Or Severe Active Central Nervous System Lupus. Benlysta Has Not Been Studied In Combination With Other Biologics Or Intravenous Cyclophosphamide. Use Of Benlysta Is Not Recommended In These Situations. Benlysta Is A B-Lymphocyte Stimulator (Blys)-Specific Inhibitor Indicated For The Treatment Of Patients Aged 5 Years And Older With Active, Autoantibody-Positive, Systemic Lupus Erythematosus Who Are Receiving Standard Therapy. ( 1 ) Limitations Of Use: The Efficacy Of Benlysta Has Not Been Evaluated In Patients With Severe Active Lupus Nephritis Or Severe Active Central Nervous System Lupus. Benlysta Has Not Been Studied In Combination With Other Biologics Or Intravenous Cyclophosphamide. Use Of Benlysta Is Not Recommended In These Situations. ( 1 )
|